Bristol-Myers Squibb’s Stock Looks Cheap on the Surface, but Hidden Risks Lurk Beneath Jun 2, 2026 Life Science
5 Institutional-Approved High-Dividend Pharmaceutical Stocks for Passive Income Investors May 29, 2026 Life Science
Riding on Strong Earnings and a $1.5 Billion Market Catalyst, Exelixis Is Poised for Takeoff May 28, 2026 Life Science
Is It Wise to Follow the Herd and Buy the Same Weight-Loss Drug Giant as the U.S. President? May 28, 2026 Life Science
Billionaires Reduce Holdings in UnitedHealth, Yet Wall Street Remains Bullish May 28, 2026 Life Science
Translating 10 Projects Weekly, Eli Lilly Launches Largest Acquisition Wave in Its History May 26, 2026 Life Science
Beyond Lilly and Novo Nordisk: Two Under-the-Radar Picks in the Obesity Drug Market May 26, 2026 Life Science
Is Pfizer’s Stock, with a Dividend Yield Exceeding 6%, Undervalued by the Market? May 25, 2026 Life Science
These Three Disruptive Stocks Are Poised to Deliver Massive Returns Over the Next Two Decades May 25, 2026 Life Science, Technology
Why Eli Lilly Is Underrated in the Red-Hot GLP-1 Weight-Loss Drug Race, per Morgan Stanley May 25, 2026 Life Science
Strong Performance in Healthcare Sector Driven by Multiple Positive Factors May 22, 2026 Life Science
Pfizer’s 50% Stock Crash: A Hidden Contrarian Buy Amid Booming Healthcare Sector May 22, 2026 Life Science
Three Recession-Resistant Stocks Worth Investors’ Attention May 22, 2026 Consumer Goods, Life Science
The Market Underestimates Bristol-Myers Squibb’s New Product Growth Potential May 21, 2026 Life Science
